Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry S Komm

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Maturitas|December 27, 2011
An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosisBarry S Komm, Arkadi A Chines
Post Reproductive Health|August 21, 2015
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breastJames H Pickar, Barry S Komm
Reviews in Endocrine & Metabolic Disorders|September 9, 2006
Wnt signaling and osteoblastogenesisPeter V N Bodine, Barry S Komm
Journal of Cellular Biochemistry|January 19, 2018
The ongoing saga of osteoporosis treatmentBarry S Komm, Peter V N Bodine
Vitamins and Hormones|March 20, 2002
Tissue culture models for studies of hormone and vitamin action in bone cellsPeter V N Bodine, Barry S Komm
Steroids|June 15, 2014
Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone lossBarry S Komm, Sebastian Mirkin, Simon N Jenkins
Expert Opinion on Drug Safety|August 8, 2013
Conjugated estrogens for the treatment of menopausal symptoms: a review of safety dataSebastian Mirkin, Barry S Komm, James H Pickar
Maturitas|August 16, 2014
Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapyStuart L Silverman, Barry S Komm, Sebastian Mirkin
Expert Opinion on Emerging Drugs|January 6, 2015
Emerging hormonal treatments for menopausal symptomsAndrea R Genazzani, Barry S Komm, James H Pickar
Menopause (New York, N.Y.)|November 1, 2017
Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding studyJames H Pickar, Joanne Lavenberg, Kaijie Pan, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Maturitas|December 27, 2011
An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosisBarry S Komm, Arkadi A Chines
Post Reproductive Health|August 21, 2015
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breastJames H Pickar, Barry S Komm
Reviews in Endocrine & Metabolic Disorders|September 9, 2006
Wnt signaling and osteoblastogenesisPeter V N Bodine, Barry S Komm
Journal of Cellular Biochemistry|January 19, 2018
The ongoing saga of osteoporosis treatmentBarry S Komm, Peter V N Bodine
Vitamins and Hormones|March 20, 2002
Tissue culture models for studies of hormone and vitamin action in bone cellsPeter V N Bodine, Barry S Komm
Steroids|June 15, 2014
Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone lossBarry S Komm, Sebastian Mirkin, Simon N Jenkins
Expert Opinion on Drug Safety|August 8, 2013
Conjugated estrogens for the treatment of menopausal symptoms: a review of safety dataSebastian Mirkin, Barry S Komm, James H Pickar
Maturitas|August 16, 2014
Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapyStuart L Silverman, Barry S Komm, Sebastian Mirkin
Expert Opinion on Emerging Drugs|January 6, 2015
Emerging hormonal treatments for menopausal symptomsAndrea R Genazzani, Barry S Komm, James H Pickar
Menopause (New York, N.Y.)|November 1, 2017
Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding studyJames H Pickar, Joanne Lavenberg, Kaijie Pan, et al.
Pageof 9